This may explain the previously observed synergistic effect of combining the RAR-agonist with ABC-inhibitory anti-cancer retinoids, such as EC19 and EC23, that can reduce their efflux, resulting in maximal synergistic interference with Caco-2 cell growth. Here, RARA is linked to cancer.